PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit

Updated: 08/30/2019

Pipeline Type

New Drugs in Development

Phase Of Development

Preclinical

Sponsors and Collaborators

Stoke Therapeutics

Mechanism of Action

Mechanism Description

STK-001 is an Antisense oligonucleotide that increases levels of SCN1a mRNA in the cell resulting in increased NaV1.1 protein production thereby restoring the reduced protein to near normal levels.

Populations Tested In

Dravet Syndrome

Other Resources

Special FDA Designation

Nonprofit or Government Support

N/A

Nonprofit or Government Support Description

N/A

Previous Presentations

Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
AEDD

Location of Clinical Trials

N/A

Clinical Trial link

Sign Up for Emails

Stay up to date with the latest epilepsy news, stories from the community, and more.